
UK’s competition regulator will refer the Australian hearing device maker Cochlear’s acquisition of Copenhagen-based Demant’s hearing implants business Oticon Medical for an in-depth investigation.
UK’s Competition and Markets Authority (CMA) said on Tuesday it would refer the 850 million Danish crowns ($121.14 million) deal to a phase 2 investigation as it could threaten competition.
Read more: EU To Probe Cochlear’s Oticon Bid
The deal is under investigation by the European Union (EU) antitrust regulators, who warned in December that the merger is a significant threat to the European market.
The CMA, which had given the companies until Dec. 13 to allay its concerns about the supply of bone conduction devices in Britain, added the companies did not offer any undertakings.
Featured News
EU Regulators Probe SES-Intelsat Deal, Seek Insight on Starlink’s Competitive Threat
May 12, 2025 by
CPI
Trump Removes Copyright and Library of Congress Leaders After AI Policy Rift
May 12, 2025 by
CPI
Delta, Korean Air Buy Into WestJet in Major Cross-Border Deal
May 12, 2025 by
CPI
Trump Targets Big Pharma With Tough New Drug Pricing Rules
May 12, 2025 by
CPI
Geradin Partners Expands London Team with New Partner Hire
May 12, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece